Please login to the form below

Not currently logged in
Email:
Password:

Generic Zyprexa launched in US

Teva Pharmacuetical and Dr Reddy's have had a generic version of Eli Lilly & Company's blockbuster schizophrenia drug Zyprexa (olanzapine) approved by the US Food and Drug Administration

Teva Pharmacuetical and Dr Reddy's have had a generic version of Eli Lilly & Company's blockbuster schizophrenia drug Zyprexa (olanzapine) approved by the US Food and Drug Administration (FDA).

It is the first generic olanzapine product to be marketed in the US. Lilly's Zyprexa is one of the biggest-selling drugs affected by the patent cliff, achieving global sales of $5.03bn in 2010.

Lilly has already seen the first affects of generic competition for Zyprexa in its financial results for the third quarter of 2011, with sales down 3 per cent for the period.

Teva's olanzapine tablets in 2.5mg, 5mg, 7.5mg, 10mg and 15mg doses and Dr Reddy's olanzapine tablets in 20mg doses have each been awarded a 180-day period of marketing exclusivity in the US, following an agreement made between the two companies in April 2011.

In addition, Dr Reddy's will launch its 2.5mg, 5mg, 7.5mg, 10mg ,15mg and 20mg of olanzapine tablets upon expiration of the 180-day exclusivity period.

Dr Keith Webber, deputy director of the Office of Pharmaceutical Science in the FDA's Center for Drug Evaluation and Research, said: "The approval of generic olanzapine offers greater access to a widely used treatment for mental illnesses. Having affordable treatment options is good for patients with long-term illnesses that must be carefully managed."

25th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics